食管鳞癌G3BP和骨桥蛋白的表达及其对患者预后的影响

目的研究食管鳞癌组织中GTP酶激活蛋白SH3功能区结合蛋白(G3BP)和骨桥(OPN)蛋白的表达及其与食管鳞癌生物学行为之间的关系。方法采用免疫组织化学方法检测80例食管鳞癌组织中G3BP和OPN蛋白的表达情况,探讨它们与食管鳞癌的肿瘤大小、组织分化程度、TNM分期、淋巴结转移和预后的关系。结果(1)G3BP蛋白在食管鳞癌组织中的阳性表达率为71.3%,它在淋巴结转移组的阳性表达率高于无淋巴结转移组(Z=-2.283,P=0.022);而与肿瘤大小、组织分化程度、TNM分期无关(P>0.05);G3BP蛋白阳性表达组患者的术后生存时间较阴性表达组短,差异有统计学意义(P=0.000)。(2)OPN蛋白在食管鳞癌组织中的阳性表达率为100%,OPN蛋白的表达水平与组织分化程度(X~2=10.766,P=0.005)及淋巴结转移(Z=-2.289,P=0.022)有关,而与肿瘤大小和TNM分期无关(P>0.05);OPN蛋白的表达水平越高,患者术后生存时间越短(P=0.000)。(3)G3BP蛋白和OPN蛋白在食管鳞癌组织中的表达之间存在正相关性(r(?)=0.376,P=0.001)。结论食管鳞癌组织G3BP和OPN蛋白的表达与淋巴结转移情况及患者的预后有密切关系。     

胃癌组织中PTEN，VEGF，MMP-9的表达及相关性研究

目的　探讨胃癌中PTEN,VEGF,MMP-9的表达及其与胃癌生物学行为的关系。方法　应用免疫组织化学SP法检测 7 1例胃癌组织及 3 7 例远癌胃黏膜中PTEN,VEGF,MMP-9 的表达。结果　胃癌组织中PTEN蛋白表达 ( 7 1. 8% )显著低于远癌胃黏膜的表达 ( 1 0 0% ) (P < 0. 0 1 ) , 且与肿瘤的组织分化程度、浸润深度及淋巴结转移呈负相关 (均P< 0. 0 5 ),而与年龄、性别等无关 (均P> 0. 0 5 ) 。VEGF在胃癌中的表达 ( 6 2. 0% ) 显著高于远癌胃黏膜的表达 ( 2 9. 7% ) (P < 0. 0 1 ) ,且与淋巴结转移呈正相关 (P< 0. 0 1 ) ,而与年龄、性别、组织分化程度及肿块浸润深度无关 (均P> 0. 0 5 )。MMP-9在胃癌中的表达 ( 6 9% ) 显著高于远癌胃黏膜的表达 ( 4 0. 5% ) (P < 0. 0 1 ),且与淋巴结转移呈正相关 (P< 0. 0 5 ) , 而与年龄、性别、组织分化程度及癌组织浸润深度无关 (均P> 0. 0 5 )。PTEN在胃癌中的表达与VEGF和MMP-9呈负相关 (P < 0. 0 5 )。结论　胃癌中PTEN蛋白表达降低,其表达与肿瘤的组织分化程度、浸润深度及淋巴结转移密切相关,且与VEGF,MMP-9表达呈负相关。联合检测PTEN,VEGF,MMP-9有助于提高胃癌侵袭转移能力的评估,对胃癌的预后判断具有重要的临床意义。     

NGF、MMP-9在胃腺癌组织中的表达及其相关性的研究

目的:探讨神经生长因子(NGF)、基质金属蛋白酶-9(MMP-9)在胃腺癌组织中的表达及其相关性,并分析其与临床病理因素之间的关系。方法:采用免疫组织化学(EnVisionTM)法检测NGF、MMP-9在胃腺癌组织及癌旁组织中的表达。结果:NGF在癌旁组织、胃腺癌组织中的阳性表达率分别为6.66%、51.25%,两组之间差异有统计学意义(P<0.01);MMP-9在癌旁组织、胃腺癌组织中的阳性表达率为3.33%、55.00%,两组之间差异亦有统计学意义(P<0.01)。NGF的阳性表达率与患者年龄、肿瘤直径、组织学分级及浸润深度无关(P>0.05),而与淋巴结转移及神经浸润有关(P<0.01);MMP-9的阳性表达率与患者年龄、肿瘤直径、组织学分级无关(P>0.05),而与淋巴结转移、神经浸润及浸润深度有关(P<0.05)。NGF、MMP-9在胃腺癌组织中的表达呈正相关性(r=0.62,P<0.01)。结论:NGF、MMP-9在胃腺癌组织中均过表达,可能共同影响肿瘤神经浸润和淋巴结转移。     

Ki-67、AE1/AE3、p53在结直肠癌组织中的表达及其临床意义

目的 探讨Ki-67、AE1/AE3、p53在结直肠癌（CRC）患者癌组织中的表达、临床意义及相关性研究。方法 收集2021年1月至2022年6月于本院手术治疗的76例CRC患者癌组织标本，选取同病例癌旁组织标本作为对照。免疫组化法检测组织标本中Ki-67、AE1/AE3、p53表达水平，分析三种蛋白表达水平与CRC临床病理学参数之间的关系及CRC患者癌组织中三种蛋白表达之间的相关性。结果CRC患者癌组织中Ki-67、AE1/AE3、p53表达阳性率显著高于癌旁组织，存在统计学差异（P<0.05）。CRC患者癌组织中Ki-67、AE1/AE3、p53阳性表达与淋巴结是否存在转移、病理分化程度、TNM分期及浸润深度之间存在相关性（P<0.05），同时Ki-67和AE1/AE3阳性表达还与肿瘤直径之间存在相关性（P<0.05）。CRC患者癌组织中Ki-67表达与AE1/AE3和p53表达呈正相关（rs=0.591、0.334,P<0.05）;AE1/AE3表达和p53表达也呈正相关（rs=0.441,P<0.05）。结论 CRC患者Ki-67、AE1/AE3、...     

胰腺癌PTEN蛋白表达及其与p53表达相关性的研究

目的 分析胰腺癌PTEN蛋白表达以揭示其与胰腺癌生物学行为的关系,通过PTEN与p53蛋白表达相关性的研究,探讨p53突变对PTEN蛋白表达的影响。方法 应用免疫组织化学方法分析41例胰腺癌PTEN和p53蛋白表达。结果 41例胰腺癌中p53阳性表达16例。阴性表达25例;所有标本都有PTEN蛋白表达,其阳性物质定位与癌周正常组织相同,其中22例呈高表达(++),19例呈低表达(+),其表达高低与胰腺癌TNM分期有相关性(P<0.01);并与p53蛋白表达呈现相关(P<0.05);而与肿瘤分化程度无相关性。结论 胰腺癌罕见PTEN的完全失活;胰腺癌PTEN蛋白的亚细胞定位与正常组织相同;但其表达有高低之别,并与胰腺癌TNM分期有相关性,表明PTEN表达下降与胰腺癌侵袭行为及病程进展有关;而p53突变则是导致PTEN表达下降原因之一。     

直肠癌患者Ki-67、HER-2、p53表达与临床病理特征之间的关系

目的 探讨分析细胞核增殖抗原（Ki-67）、人类表皮生长因子受体-2(HER-2)和肿瘤抑制因子（p53）在直肠癌患者癌组织中的表达水平及其与临床病理特征之间的关系。方法 选取2020年6月至2023年3月于本院肛肠科行手术治疗的直肠癌患者，收集癌组织标本及同一患者的癌旁正常组织标本各80例。应用免疫组化法检测Ki-67、HER-2和p53在直肠癌患者癌组织标本中的表达水平，分析其与临床病理学资料之间的关系，并应用Spearman分析3种基因表达之间的相关性。结果 直肠癌患者癌组织标本中Ki-67、HER-2和p53表达阳性率均显著高于同一例患者的癌旁正常组织，差异存在统计学意义（P<0.05）。直肠癌患者癌组织标本中Ki-67、HER-2、p53表达阳性与TNM分期、组织学分型、脉管浸润及病理分化程度之间存在相关性（P<0.05）;Ki-67和p53表达阳性与肿瘤直径之间存在相关性（P<0.05）;Ki-67和HER-2还与淋巴结转移之间存在相关性（P<0.05），而三者均与性别之间无相关性（P>0.05）。直肠癌患者癌组织标本中Ki-67表达与HER-...     

乳腺癌抗雌激素药物耐药蛋白1在食管鳞癌血清和组织中的表达及临床意义

目的 探讨乳腺癌抗雌激素药物耐药蛋白1( BCAR1)在食管鳞癌血清和组织中的表达及临床意义.方法 采用酶联免疫吸附试验(ELISA)检测2010年2月至2011年1月间46例食管鳞癌患者和25例正常人血清BCAR1水平;应用组织芯片和免疫组织化学方法检测2004年2月至2006年7月间106例食管鳞癌和癌旁正常组织中BCAR1表达.结果 食管鳞癌组BCAR1血清水平显著高于正常对照组(P＜0.01);晚期食管鳞癌BCAR1血清水平显著高于早期食管鳞癌组和正常对照组(P＜0.01);切除肿瘤后,血清BCAR1水平有逐渐下降趋势.BCAR1蛋白在食管鳞癌组织中阳性率为97％( 103/106),癌旁正常食管组织中有16例弱阳性,阳性率为15％ (16/106),两者差异有统计学意义(P＜0.01);BCAR1阳性表达与食管鳞癌的分化明显相关(P＜0.05),与年龄、性别、淋巴结转移、浸润深度和TNM分期明显无关(P＞0.05).生存分析提示BCAR1高表达组生存时间少于低表达组(P＜0.01);经COX模型多因素生存分析,显示BCAR1表达和淋巴结转移为独立预后因素.结论 食管鳞癌血清和组织中BCAR1水平显著高于正常对照组,并与疾病进展、治疗效果、分化程度和预后相关,可作为食管鳞癌诊断和判断预后重要新的肿瘤分子标记.     

同源盒A10和P53蛋白在结直肠癌中的表达及其临床意义

目的 研究结直肠癌组织中同源盒A10(HOXA10)和P53蛋白表达与临床病理特征及预后的关系。方法 收集2017年4月至2019年10月在西安市中心医院行手术治疗的97例结直肠癌患者的组织标本,采用免疫组织化学染色法检测癌组织及对应癌旁正常组织中HOXA10和P53蛋白表达情况。分析HOXA10和P53蛋白表达与临床病理特征的关系;Spearman相关性分析结直肠癌组织中HOXA10和P53表达的相关性;Kaplan-Meier生存曲线分析HOXA10和P53蛋白表达与患者术后生存率的关系。结果 97例结直肠癌组织中HOXA10和P53蛋白阳性表达率为74.2%和68.0%,对应癌旁正常组织中阳性表达率为35.1%和29.9%,差异均有统计学意义(P<0.001)。结直肠癌组织中HOXA10和P53蛋白表达呈正相关(r=0.657,P<0.05)。结直肠癌组织中HOXA10蛋白表达与TNM分期、分化程度、淋巴结转移及浸润深度有关,P53蛋白表达与肿瘤直径、TNM分期、分化程度、淋巴结转移、脉管浸润及浸润深度有关,差异均有统计学意义(P<0.05)。随访32(5～61...     

CD105蛋白在食管鳞癌中的表达及其与P53蛋白表达的关系

目的探讨CD 105蛋白在食管鳞状细胞癌(鳞癌)组织中的表达,及其与P 53蛋白表达的关系。方法应用免疫组织化学链霉菌抗生物素蛋白-过氧化酶连接法(SP法)检测CD 105蛋白和P 53蛋白在10例正常食管组织及86例食管鳞癌组织中的表达。结果CD 105蛋白在正常食管组织中不表达,86例食管鳞癌组织中表达阳性率为74.4%(64/86)。早期食管鳞癌(Ⅰ~Ⅱ期)患者的CD 105蛋白表达阳性率为66.1%(37/56),晚期(Ⅲ~Ⅳ期)为90.0%(27/30),两者比较差别有统计学意义(P<0.05);食管鳞癌组织中P 53蛋白表达阳性、阴性者中,CD 105蛋白表达阳性率分别为87.1%(54/62)、41.7%(10/24),两者比较差别有统计学意义(P<0.05)。结论CD 105蛋白在食管鳞癌的发生中起重要作用,其表达与食管鳞癌的临床分期及组织中P 53蛋白的异常表达呈正相关。     

食管鳞癌与细胞因子信号转导负调控因子3及其DNA甲基化的关系

目的 检测食管鳞癌(ESCC)组织中细胞因子信号转导负调控因子3(SOCS3)的DNA甲基化、mRNA及蛋白表达水平,探讨其在食管鳞癌发生、发展、浸润和转移中的作用.方法 采用甲基化特异性聚合酶链反应(MSP)、Real-Time聚合酶链反应(PCR)和Western blot法分别检测43例食管鳞癌组织中SOCS3的DNA甲基化、mRNA和蛋白表达水平,并与相应的癌旁正常食管组织进行对照研究,分析其与临床病理参数的关系.结果 (1)食管鳞癌组织SOCS3 DNA甲基化的阳性率(79.1%)明显高于癌旁组织(14.0%,P＜0.01);(2)食管鳞癌组织SOCS3 mRNA相对表达强度比值(0.53±0.30)明显低于癌旁组织(1.15±0.44,P＜0.01),食管鳞癌组织中甲基化组的SOCS3 mRNA表达(0.45±0.24)显著低于非甲基化组(0.86±0.29,P＜0.05);(3)食管鳞癌组织SOCS3蛋白表达(1.66±0.22)显著低于癌旁组织(1.83±0.15,P＜0.01),食管鳞癌组织中甲基化组SOCS3蛋白表达(1.61±0.21)显著低于非甲基化组(1.87±0.15,P＜0.01);(4)在TNM分期中Ⅲ期组表达均低于Ⅰ～Ⅱ期组(P＜0.05),伴有淋巴结转移组表达也都低于无淋巴结转移组(P＜0.05),未发现其在性别、年龄、家族史、吸烟史中有明显差异(P＞0.05);(5)食管鳞癌组织中SOCS3mRNA表达及其蛋白表达水平与肿瘤分化级别呈正相关(0.301＜r＜1,P＜0.05),与TNM分期、淋巴结转移呈负相关(-1＜r＜-0.301,P＜0.05).结论 食管鳞癌组织中SOCS3 DNA甲基化阳性率高,导致SOCS3基因表达下调,与食管鳞癌的分化、浸润和转移密切相关.     

Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer

BACKGROUND: p53 gene mutation and abnormal p53 protein expression, also loss of the retinoblastoma gene and protein expression are frequently associated with esophageal squamous cell carcinoma (ESCC). Recently, the prognostic significance of the combined analysis of p53 protein and retinoblastoma protein (pRB) has been reported in non-small cell lung cancer. However, in ESCC, the prognostic significance of the combined analysis of these proteins remains unclear. In this study, we immunohistochemically analyzed the p53 protein and pRB expressions in surgically resected ESCC, and we evaluated the prognostic significance of the combination of these proteins. METHODS: We analyzed p53 protein and pRB expressions immunohistochemically in 191 surgically resected ESCC cases. Overexpression of p53 and loss of pRB were considered abnormal. RESULTS: Overexpression of p53 protein was detected in 79 patients (41%) and decreased pRB nuclear staining occurred in 82 (43%). The Kaplan-Meier survival curve showed that absence of pRB expression was significantly associated with shortened survival (p = 0.001), whereas expression of p53 was not significantly associated with survival. Moreover, p53 and pRB status individually were not independent prognostic factors in multivariate survival analysis. With respect to pRB and p53, the tumors could be grouped into four categories: p53-/pRB+ (31%); p53-/pRB- (27%); p53+/pRB+ (26%); and p53+/pRB- (16%). Favorable prognosis was observed in patients with p53-/pRB+ tumors. Multivariate analysis showed p53-/pRB+ status to be an independent prognostic factor. CONCLUSIONS: The combination of p53 protein loss and pRB expression was associated with good prognosis in patients with ESCC.     

结直肠癌组织中p53、PTEN和VHL对缺氧诱导因子-1α表达的影响

目的研究结直肠癌组织中p53、PTEN和VHL对缺氧诱导因子-1α（hypoxia—inducible fac—tor 1α）表达的影响及意义。方法采用组织芯片技术制作60例结直肠癌组织芯片,同时采用SP免疫组织化学法和原位分子杂交（cDNA—mRNA）方法检测结直肠癌组织芯片中p53、PTEN、VHL、HIF—1α和HIF-1α mRNA的表达。结果60例结直肠癌组织中,p53、PTEN、VHL、HIF-1α和HIF-1α mRNA的阳性率分别为55％、48．3％、41．7％、58．3％和71．7％。淋巴结转移组p53、HIF-1α和HIF-1α mRNA阳性率显著高于无淋巴结转移组（P〈0．01）。p53高表达、PTEN和VHL低表达与HIF-1α和HIF-1α mRNA高表达明显相关。结论p53、PTEN、VHL、HIF-1α和HIF-1α mRNA的表达水平可以作为评估结直肠癌预后的参考指标。     

Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy

BACKGROUND: Squamous cell carcinoma of the esophagus (ESCC) is radiosensitive; however, surgeons frequently encounter ESCC that survives radiotherapy to grow more rapidly and invasively. This alteration of tumor behavior may result from tumor hypoxia induced by radiotherapy. METHODS: Forty-four patients with advanced (T3 and T4) ESCC, who underwent radiotherapy before operation, either with 40 Gy for preoperative treatment or 60 Gy or more for radical treatment, and 44 patients without preoperative therapy were subjected to retrospective immunohistochemical study. CD34 for tumor vessels, glucose transporter 1 (GLUT1) which was induced by hypoxia, MIB-1 for proliferating activity, and p53 were stained for surgical samples from ESCC patients. Tumor tissue at the invading front was the focus of evaluation. Macroscopic morphologic differences of ESCC were also evaluated. RESULTS: Loss of esophageal wall thickness and deep ulceration were morphologic characteristics of ESCC after radiotherapy. Tumor vessel density was reduced and GLUT1 expression was greater in the ESCC after radiotherapy than in those without treatment. Tumor vessel density was similar for both preoperative and radical radiotherapy samples, while GLUT1 expression tended to be greater in the latter than in the former. The expression of MIB-1 and p53 did not show any significant difference between ESCC with or without radiotherapy. CONCLUSIONS: Reduced vessel density and increased GLUT1 expression suggested tumor hypoxia for ESCC occurred after radiotherapy. Tumor hypoxia would induce ulcerative and invasive growth, which is a great obstacle to clinical treatment of residual or relapse ESCC after radiotherapy.     

STAT3在食管鳞状细胞癌中的表达和意义

目的研究STAT3蛋白表达与食管鳞状细胞癌临床病理特征的关系,探讨其在食管癌变中的可能作用。方法应用免疫组织化学S-P法检测60例食管鳞状细胞癌及其癌旁组织中STAT3蛋白的表达,结合临床资料进行分析。结果STAT3蛋白阳性反应主要定位于胞质。食管鳞状细胞癌组织中STAT3蛋白表达阳性率86.7%(平均灰度值为36.05±13.74)明显高于正常组织阳性率17.6%(平均灰度值为16.92±5.43)(P<0.05)。STAT3蛋白在低分化、中分化、高分化鳞癌组的阳性表达率分别是100%、95%、73.08%,平均灰度值分别是51.22±7.09、42.18±7.21、23.16±6.94,3组间差异有统计学意义(P<0.01)。肿瘤分化程度越高STAT3蛋白表达越低。有淋巴细胞转移的食管癌组织中STAT3表达的阳性率100%(平均灰度值45.36±10.36),明显高于无淋巴细胞转移的食管癌组织阳性率78.38%(平均灰度值30.26±12.41)(P<0.05)。结论STAT3蛋白在食管鳞状细胞癌组织中的高表达可能与食管鳞癌的发生有关系。     

Osteopontin Expression in Squamous Cell Cancer of the Esophagus

BACKGROUND: The purpose of this study was to better understand the role of osteopontin (OPN) in esophageal squamous cell carcinoma (ESCC) by comparing the OPN mRNA level in ESCC tumor tissue and matched normal tissue and by determining the prognostic significance of the gene expression. METHODS: Initially, by an oligo-nucleotide microarray hybridization technique, OPN expressions were found to consistently elevate at least twofold in three ESCC tissues compared with their adjacent normal ones. Subsequently, the expression of OPN mRNA was detected by real-time QRT-PCR among the 58 fresh surgical ESCC specimens. The clinical information was obtained by chart review. RESULTS: OPN mRNA expression was detectable in 58 of 58 (100%) tumor specimens and 57 of 58 (98.3%) nonmalignant esophageal specimens. OPN expression was higher in tumor tissue than in the matched normal tissue in 54 of 58 (93.1%) individual cases. The overall median mRNA expression level of OPN was approximately 8.8-fold higher in tumor tissues (4.1; range: 0.02-247) compared with matched normal esophageal tissues (0.5; range, 0.0-21.4; p < 0.001). Overexpression of OPN mRNA was significantly associated with clinical stage (p = 0.01). The more severe the clinical stage (from I-II, III, to IV) was the higher frequency of overexpression of OPN mRNA. No significant associations were found between overexpression of OPN mRNA and the patients' survival (p = 0.27). DISCUSSION: Our findings suggest OPN is associated with esophageal tumorigenesis and progression, but not patients' survival.     

Altered E-Cadherin Expression and p120 Catenin Localization in Esophageal Squamous Cell Carcinoma

Background E-cadherin is a well-known tumor suppressor and its dysregulated expression correlates with tumor differentiation, metastasis and survival in esophageal squamous cell carcinoma (ESCC). p120 catenin is an Armadillo protein normally bound to E-cadherin in the cadherin–catenin complex at the adherens junction. Dysregulated expression and mislocalization of p120ctn affect the protective function of the complex. The objective of the present study was to evaluate the clinical significance of E-cadherin and p120ctn expression in ESCC. Methods Immunohistochemistry was performed to investigate the expression of E-cadherin and p120ctn proteins in 71 patients with ESCC. The relationships between protein expression and clinicopathological characteristics were analyzed. Results Reduced E-cadherin and p120ctn expressions were observed in 42.3% and 8.5% of ESCC cases, respectively. Reduction of membranous p120ctn was observed in 33.8% of cases. Membranous E-cadherin was preserved when p120ctn co-localized on the membrane of tumor cells (72.3%, P = 0.001). High level E-cadherin expression and membranous p120ctn preservation positively correlated with tumor differentiation (P = 0.001 and P = 0.008, respectively). p120ctn expression was also significantly related to lymph node metastasis (P = 0.003). Heterogeneous expression of both E-cadherin and p120ctn was observed in dysplasia. Conclusions Altered E-cadherin expression and p120ctn localization were related to tumor differentiation, indicating their important roles in the pathogenesis of ESCC.     

Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma

Background

While chemoradiation therapy (CRT) is one of the most useful treatments for esophageal squamous cell carcinoma (ESCC), it is important to predict response prior to treatment by using markers because some patients respond well and others do not.

Methods

Fifty-nine patients with ESCC were treated with neoadjuvant CRT at the Kagoshima University Hospital. The expression of seven types of biomarker candidate proteins in biopsy specimens of untreated primary tumors was evaluated to determine whether it correlated with response and prognosis.

Results

The positive expression rates were 47% for p53, 83% for CDC25B, 68% for 14-3-3sigma, 76% for p53R2, 75% for ERCC1, 32% for Gli-1, and 54% for Nrf2. In terms of histological response, tumor grade of the 59 patients was 48.8% for grade 1 as the non-responder, 29.2% for grade 2, and 22.0% for grade 3 as the responder. CRT was significantly effective in p53(?), p53R2(?), ERCC1(?), and Nrf2(?) tumors, while p53(?), p53R2(?), and ERCC1(?) were factors independently correlated with effective histological response. Their combined expression of two or three negative expressions had 100% effective response and was a significant prognostic factor.

Conclusion

Our results suggest that two or three negative expressions of p53, p53R2, and ERCC1 in biopsy specimens of primary tumors were associated with a favorable response to CRT for ESCC. Assessment of tumor suppressor and DNA repair protein expressions in biopsy specimens may be useful for the potential utility of CRT therapy for patients with ESCC prior to treatment.

     

Correlation of p53 Status with the Response to Chemotherapy-Based Treatment in Esophageal Cancer: A Meta-Analysis

Background

The value of p53 status for predicting response to chemotherapy-based treatment in patients with esophageal cancer has been controversial. We conducted a meta-analysis to elucidate the correlation of p53 status with the response to chemotherapy-based treatment.

Methods

Studies were searched in PubMed, Embase, and Web of Science (up to September 2012). The p53 status and response to therapy were defined and standardized. Subgroup analyses based on the treatment and histopathology were performed to explore the usefulness of p53 status for predicting response to therapy in esophageal cancer. Sensitivity analyses were conducted by removing specific studies to assess the effects of study quality.

Results

We included 28 studies with 1497 cases in our meta-analysis. Wild-type form of p53 status (low expression of p53 protein and/or wild-type p53 gene) was associated with high response to chemotherapy-based treatment in esophageal cancer (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03–1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06–1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00–1.17, P = .040). The similar correlation between the wild-type form p53 and response to therapy were also detected in subgroup analyses (total MR, pathological MR, and total CR in chemoradiotherapy subgroup; total MR in chemotherapy subgroup; total MR and pathological CR in esophageal squamous cell carcinoma [ESCC]). Additionally, patients with wild-type form p53 status had high pathological complete response rate to neoadjuvant chemoradiotherapy in ESCC.

Conclusions

The current meta-analysis suggested that p53 status might be a predictive biomarker for response to chemotherapy-based treatment in esophageal cancer.